The promise and failures of epigenetic therapies for cancer treatment
about
Synthesis of lysine methyltransferase inhibitorsHistone modifications and a choice of variant: a language that helps the genome express itselfHistone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited successTLR ligands, but not modulators of histone modifiers, can induce the complex immune response pattern of endotoxin tolerance in mammary epithelial cells.Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsMicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells.Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.Epigenetic drugs against cancer: an evolving landscape.Antiviral therapies and prospects for a cure of chronic hepatitis B.Molecular characterization and targeted therapeutic approaches in breast cancerConsequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cellsGenetic Determinants of Epigenetic Patterns: Providing Insight into Disease.Conformationally Constrained Peptidomimetics as Inhibitors of the Protein Arginine Methyl Transferases.Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array.A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.Epigenetic molecular recognition: a biomolecular modeling perspective.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.Epigenetics in the hematologic malignancies.Targeting chromatin to improve radiation response.Development and the epigenome: the 'synapse' of gene-environment interplay.Endoplasmic reticulum stress, genome damage, and cancer.Addressing intra-tumoral heterogeneity and therapy resistance.BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo.The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.Genetics and epigenetics of pediatric leukemia in the era of precision medicineInterplay between hepatitis B virus and innate immune signaling pathways
P2860
Q26799953-62420E64-839F-4C1C-8DEF-03F9D57B31C9Q26823316-7926E4AC-53F8-42AB-A96B-D1C2CB389526Q28822336-CCFA7B2B-7BB7-465E-9E0B-2198ED4C6908Q33620264-66EACA1C-F9D4-43BC-9A41-7D45A754264CQ33801377-B24B6B62-2480-40B6-A709-C5C500E881FFQ33808084-86F333B4-C54E-4BC5-8A8C-0E3FCC12EA32Q34211637-35AE6F36-8A10-44BF-B7AD-92869C15AF58Q34431964-F71638BF-BAD2-4297-B2E3-E9F31673E827Q35245231-4787E3B4-8CF8-4BF7-A055-96689F9A2783Q35530143-23A489F7-263A-4BEB-B6E7-B43B86F27FBDQ36020996-8708A9E5-8725-4A88-868F-23396B68E573Q36025711-764FF236-3F67-43C0-A8ED-0A2555AF7E3CQ36102115-8351C7C4-570B-4921-A022-598B440ED41BQ37698595-3E671106-1D3D-46B5-8E9F-6F4A153FD191Q37705920-1D04D405-37FC-41C4-A797-F90C5079A0CCQ38195005-69469796-189B-4F34-99C9-FF6846B547B4Q38199723-E178C42D-8486-42F5-9518-2C6530213009Q38282809-A455380C-6D55-4C3F-8DB0-A7A1A7B90957Q38290243-3B6B2D93-731F-47D7-8B9D-844FD53E9536Q38302721-F9478B43-2A15-4688-974D-C1D6AFD934FCQ38359856-61DE64C6-8F49-45BD-AFCF-3C9EBA86A67CQ38823179-3733A070-7BFD-47EC-95B2-24200DF313F0Q39010963-7806B5D8-6A3C-4158-8C89-D2673B98183BQ39954100-1C07AF99-61D3-4FC8-8EE5-4423A2E293D2Q47445768-B5C385E4-836A-4F36-BA36-F37691FF77C9Q57175475-0BA16EFB-B2F2-4190-993B-03836A1F3863Q57207207-F8E732DB-613A-4A38-A6CF-77D86FBFB3E5
P2860
The promise and failures of epigenetic therapies for cancer treatment
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The promise and failures of epigenetic therapies for cancer treatment
@en
type
label
The promise and failures of epigenetic therapies for cancer treatment
@en
prefLabel
The promise and failures of epigenetic therapies for cancer treatment
@en
P2860
P1476
The promise and failures of epigenetic therapies for cancer treatment
@en
P2093
Kenneth S Ramos
Pasano Bojang
P2860
P304
P356
10.1016/J.CTRV.2013.05.009
P577
2013-07-05T00:00:00Z